DA Davidson upgraded Clearwater Analytics (CWAN) to Buy from Neutral with a price target of $32, down from $35. The company's ...

In a report released today, Julian Harrison from BTIG reiterated a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report), with a ...

BTIG analyst Mark Massaro maintained a Buy rating on Castle Biosciences (CSTL – Research Report) today and set a price target of $40.00. The ...

Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

On Friday, BTIG initiated coverage on ImmunityBio Inc (NASDAQ:IBRX) with a Buy rating and a price target of $6.00. The firm sees potential in the company's lead product, ANKTIVA, an IL-15 receptor ...

BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (BIT:1PANW) from Buy to Neutral. There are 3,043 funds or institutions reporting positions in Palo Alto ...

BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am. Discover outperforming stocks and invest smarter with ...

On Friday, BTIG initiated coverage on ImmunityBio Inc (NASDAQ:IBRX) with a Buy rating and a price target of $6.00. The firm sees potential in the company's lead product, ANKTIVA, an IL-15 receptor ...

In light of these considerations, Zelin updated BTIG's model to reflect a more moderate differentiation of briquilimab versus barzolvolimab and the decreased likelihood of a Q12W regimen. Despite the ...